Vaxart Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Steven Lo

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	2.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Steven Lo (56 yo)

less than a year

Permanencia

Mr. Steven Lo serves as President, CEO & Director of Vaxart, Inc. since March 18, 2024. He has been Director at Zosano Pharma Corporation since October 2019 and serves as its President and Chief Executive...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sean Tucker	Senior VP & Chief Scientific Officer	14.3yrs	US$1.14m	0.13% $ 2.8m
James Cummings	Chief Medical Officer	2.8yrs	US$1.17m	0.082% $ 1.7m
Steven Lo	President	less than a year	sin datos	sin datos
Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	1.4yrs	sin datos	0.044% $ 919.9k
Raymond Stapleton	Chief Technology Officer	1.8yrs	sin datos	sin datos
Edward Berg	Senior VP & General Counsel	2.3yrs	sin datos	0.064% $ 1.3m
Shaily Garg	Senior Vice President of Clinical Development & Project Management	4.2yrs	sin datos	sin datos
Rajesh Kapoor	Senior Vice President of Quality	3.3yrs	sin datos	sin datos

2.5yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de VXRT * se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Steven Lo	President	less than a year	sin datos	sin datos
Robert Yedid	Independent Director	4.6yrs	US$92.26k	0.0063% $ 131.6k
Harry Greenberg	Member of Scientific & Clinical Advisory Board	2.8yrs	sin datos	sin datos
Elaine Heron	Independent Director	1.8yrs	US$89.08k	0.0044% $ 92.5k
Michael Finney	Independent Chairman of the Board	6.3yrs	US$109.57k	0.38% $ 7.9m
Stefan Gravenstein	Member of Scientific & Clinical Advisory Board	2.8yrs	sin datos	sin datos
David Wheadon	Independent Director	3.1yrs	US$93.72k	0.0042% $ 87.3k
Robert Belshe	Member of Scientific & Clinical Advisory Board	2.8yrs	sin datos	sin datos
William Watson	Independent Director	1.8yrs	US$94.76k	0.014% $ 294.8k
Marion Pepper	Member of Scientific & Clinical Advisory Board	2.8yrs	sin datos	sin datos
Ralph Baric	Member of Scientific & Clinical Advisory Board	2.8yrs	sin datos	sin datos
Gregory Gray	Member of Scientific & Clinical Advisory Board	2.8yrs	sin datos	sin datos

2.8yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de VXRT * no se considera experimentada (2.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Vaxart Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Less than half of directors are independent

Less than half of directors are independent

Vaxart, Inc. Announces CEO Changes

Recent updates

Vaxart, Inc. to Report Q1, 2024 Results on May 13, 2024

High number of new and inexperienced directors

Vaxart, Inc., Annual General Meeting, Jun 11, 2024

Vaxart, Inc. to Report Fiscal Year 2023 Results on Mar 14, 2024

Vaxart, Inc. Announces Chief Executive Officer Changes

Less than half of directors are independent

Less than half of directors are independent

Nasdaq Notifies Vaxart's Eligibility for an Additional 180-Day Compliance Period, or Until July 15, 2024, to Regain Compliance with the Bid Price Requirement

Vaxart, Inc. Announces CEO Changes

Vaxart, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers

Vaxart, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Market cap size

High number of new and inexperienced directors

Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate

Vaxart, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Vaxart Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Non-Compliance with the $1.00 Minimum Bid Price Requirement

High number of new and inexperienced directors

Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

High number of new and inexperienced directors

Vaxart, Inc.(NasdaqCM:VXRT) dropped from Russell 2000 Dynamic Index

Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate

First quarter 2023 earnings released: US$0.19 loss per share (vs US$0.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate

Director recently bought Mex$294k worth of stock

Vaxart, Inc. Names Phillip Lee as Chief Financial Officer

High number of new and inexperienced directors

Vaxart, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

Vaxart, Inc. Appoints Ray Stapleton as Chief Technology Officer

Vaxart, Inc. Announces Board Changes

Vaxart, Inc. Appoints W. Mark Watson to Its Board of Directors

Vaxart, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Vaxart, Inc. Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

High number of new and inexperienced directors

Key Executive recently bought Mex$322k worth of stock

High number of new and inexperienced directors

Vaxart, Inc. Presents New Preclinical Data Demonstrate Two of it's COVID-19 Vaccine Candidates Protect Against Omicron

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

High number of new and inexperienced directors

Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission

Vaxart, Inc. Announces Management Changes

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2021)

No longer forecast to breakeven

High number of new and inexperienced directors

Margaret Echerd Notifies as Senior Vice President and Principal Accounting Officer of Vaxart, Inc, Effective as of May 5, 2022

High number of new and inexperienced directors

Vaxart, Inc. Appoints Edward B. Berg as Senior Vice President and General Counsel

High number of new and inexperienced directors

Forecast to breakeven in 2024

Forecast to breakeven in 2024

High number of new and inexperienced directors

High number of new and inexperienced directors

Vaxart to Test Cross-Reactivity of Its Covid-19 Oral Tablet Vaccine Against Omicron

High number of new and inexperienced directors

Vaxart, Inc. (NasdaqCM:VXRT) acquired KindredBio's manufacturing equipment and GMP manufacturing facility in California from Kindred Biosciences, Inc.

No longer forecast to breakeven

High number of new and inexperienced directors

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.075 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.075 loss in 3Q 2020)

Forecast to breakeven in 2023

High number of new and inexperienced directors

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.12 loss in 2Q 2020)